Skip to main content

Table 3 Response rates in 22 patients with mixed cryoglobulinaemia following treatment with direct-acting antiviral agents at the end of treatment and sustained virological response 12 weeks after therapy

From: Direct-acting antiviral agents in the therapy of hepatitis C virus-related mixed cryoglobulinaemia: a single-centre experience

Type of response

pIFN-α/RBV [19], n (%)

DAAs therapy, n (%)

EoT

p Value

Power

SVR12

p Value

Power

Complete

5 (33.3)

17 (77.3)

0.0008

0.895

14 (63.7)

0.030

0.867

Partial

5 (33.3)

4 (18.2)

0.216

0.801

5 (22.7)

0.553

0.895

SVR only

5 (33.3)

1 (4.5)

0.010

0.926

3 (13.6)

0.102

0.830

  1. Abbreviations: DAA Direct-acting antiviral agent, EoT End of treatment, pIFN-α Pegylated interferon-α, RBV Ribavirin, SVR12 Sustained virological response 12 weeks after therapy completion
  2. Results achieved with pIFN-α/RBV regimen are given by comparison
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us